Results 1 to 10 of about 1,751 (120)
Post-finasteride syndrome, [PDF]
Anais Brasileiros de Dermatologia, 2020 Finasteride is a 5α-reductase enzyme inhibitor that has been approved for the treatment of male androgenic alopecia since 1997. Over time, it has been considered a safe and well-tolerated drug with rare and reversible side effects.
Ana Francisca Junqueira Ribeiro Pereira +1 more
doaj +5 more sources
Post-finasteride syndrome: An emerging clinical problem [PDF]
Neurobiology of Stress, 2020 The presence of side effects during pharmacological treatment is unfortunately a quite common problem. In this review, we focused our attention on adverse events related to 5 alpha-reductase (5α-R) inhibitors (i.e., finasteride and dutasteride), approved
Silvia Diviccaro +2 more
doaj +4 more sources
Post-finasteride syndrome: our current knowledge
Вестник урологии, 2020 5-α reductase inhibitors are effective and commonly used medications for the treatment of benign prostatic hyperplasia. However, there are some questions about the safety of such medications.
A. A. Galushkin +2 more
doaj +3 more sources
5α-Reductase Isoenzymes: From Neurosteroid Biosynthesis to Neuropsychiatric Outcomes [PDF]
NeuroSci5a-reductase (5a-R) isozymes are essential for androgen metabolism and neurosteroid biosynthesis, linking endocrinology and neuropsychiatry. This systematic review, conducted in accordance with PRISMA 2020 guidelines, aimed to synthesize current evidence
Carmen Rodriguez-Cerdeira
doaj +2 more sources
Exploration of the Possible Relationships Between Gut and Hypothalamic Inflammation and Allopregnanolone: Preclinical Findings in a Post-Finasteride Rat Model [PDF]
BiomoleculesBackground: Finasteride, a 5α-reductase inhibitor commonly prescribed for androgenetic alopecia, has been linked to persistent adverse effects after discontinuation, known as post-finasteride syndrome (PFS).
Silvia Diviccaro +10 more
doaj +2 more sources
Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024. [PDF]
PLoS ONEBackgroundFinasteride is commonly utilized in clinical practice for treating androgenetic alopecia, but real-world data regarding the long-term safety of its 0adverse events(AEs) remains incomplete, necessitating ongoing supplementation.
Xiaoling Zhong +3 more
doaj +2 more sources
Epidemiological landscape of androgenetic alopecia in the US: An All of Us cross-sectional study. [PDF]
PLoS ONEBackgroundAndrogenetic alopecia (AGA) is extremely prevalent with a multifactorial etiology.MaterialsWe conducted a cross-sectional study using the All of US (AoU) dataset Sept 2024 to better understand the epidemiology, social determinants and ...
Aditya K Gupta +2 more
doaj +2 more sources
Pharmacological Management of Pattern Hair Loss
Indian Journal of Plastic Surgery, 2021 Pattern hair loss (PHL) is a condition that worsens with time and the only way it can be slowed down is with pharmacological intervention. Pharmacological treatments for PHL, from an evidenced-based perspective with respect to safety and efficacy, are ...
Sandeep Suresh Sattur +1 more
doaj +1 more source
European Urology Open Science, 2023 Finasteride competitively inhibits 5α-reductase (5-AR) isoenzymes, which blocks dihydrotestosterone (DHT) production, thereby reducing DHT. Finasteride is used in the management of benign prostatic hyperplasia (BPH) and androgenic alopecia.
Haidar Al Saffar +5 more
doaj +1 more source
Biomolecules, 2022 The treatment with finasteride (i.e., an inhibitor of 5α-reductase) may be associated with different side effects (i.e., depression, anxiety, cognitive impairment and sexual dysfunction) inducing the so-called post finasteride syndrome (PFS).
Silvia Diviccaro +6 more
doaj +1 more source